SCHEMBL20545876

SCHEMBL20545876

Cn1c(=O)c2[nH]c(=O)oc2c2cccnc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 2/20 0.47
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
MAPT P10636 1/20 0.37
KDM4E B2RXH2 2/20 0.36
HTT P42858 1/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
TNKS O95271 1/20 0.36
AURKA O14965 1/20 0.36
PARP1 P09874 1/20 0.36
CYP1A2 P05177 3/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
HPGD P15428 1/20 0.35
CYP1B1 Q16678 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11712411 0.70 ALDH1A1 (0.48) FEN1MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL15432334 0.69 FEN1 (0.53) FEN1KDM4EEGFRSRCTNKS
SCHEMBL11240235 0.68 FEN1 (0.51) FEN1KDM4EEGFRSRCTNKS
SCHEMBL3197634 0.68 FEN1 (0.55) FEN1MAPTKDM4EHTTPOLB
SCHEMBL6027612 0.68 FEN1 (0.55) FEN1ADORA3ADORA2AADORA1MAPT
SCHEMBL299224 0.67 FEN1 (0.73) FEN1ADORA3ADORA2AADORA1KDM4E
SCHEMBL1609990 0.67 FEN1 (0.56) FEN1MAPTKDM4EHTTEGFR
SCHEMBL5549672 0.66 PDE2A (0.58) FEN1ADORA3ADORA2AADORA1KDM4E
SCHEMBL13402676 0.66 FEN1 (0.56) FEN1ADORA3ADORA2AMAPTKDM4E
SCHEMBL25703950 0.65 NQO2 (0.54) FEN1KDM4EHTTTNKSCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
CN-110914242-B Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2023-07-25 CN disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 FEN1 4264/4885ADORA3 84/4885ADORA2A 306/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 FEN1 4264/4885ADORA3 84/4885ADORA2A 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.